The study plans to evaluate the impact of a personalized approach to breast cancer screening over an annual mammogram.
Laura Esserman, professor in the Department of Surgery and Radiology at the UCSF Helen Diller Comprehensive Cancer Center has always been an out-of-the-box thinker. Now, as she leads the Athena Breast Health Network, they are ready to launch the WISDOM (Women Informed to Screen Depending on Measures of Risk) study, which will evaluate the impact of a personalized approach to breast cancer screening over an annual mammogram.
As October, the Breast Cancer Awareness Month, rolls in Dr Esserman lists some important information about breast cancer to improve women's understanding of the disease:
"The essence of precision medicine is being able to tailor treatment to biology, patient preference and clinical performance," according to Esserman.
Read more here.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer
October 24th 2024Moderate prediagnosis adherence to dietary guidelines was associated with improved survival rates among Black women with high-grade serous ovarian cancer, the most common and lethal type of ovarian cancer.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More